Rating Change
UBS analysts reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) on July 13, 2026.
reiterateNYSE:LLY
UBS Reiterates Buy Rating on Eli Lilly and Company (LLY)
Rating Change UBS analysts reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) on July 13, 2026. Market Context Eli Lilly and Company operates in the Healthcare sector.…
Market Context
Eli Lilly and Company operates in the Healthcare sector. The stock currently trades at $1185.08 with a market capitalization of $906.5B. The stock has gained 28.6% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eli Lilly and Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eli Lilly and Company
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | UBS | Buy | N/A |
| Jul 13, 2026 | Guggenheim | Buy | N/A |
| Jul 10, 2026 | B of A Securities | Buy | N/A |
| Jul 08, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 08, 2026 | Truist Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LLY Stock Page
Frequently Asked Questions
What does a Buy rating mean for LLY?
A Buy rating from UBS reflects the analyst's outlook on Eli Lilly and Company (NYSE:LLY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LLY forecast page.
